Research Topics
Genomes and Genes
Species | D F EastonSummaryAffiliation: University of Cambridge Country: UK Publications
| Collaborators
|
Detail Information
Publications
Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13D F Easton
CRC Genetic Epidemiology Unit, Institute of Public Health, Cambridge, United Kingdom
Am J Hum Genet 61:120-8. 1997..89, based on five possible carriers) were also observed. One case of ocular melanoma, as well as a second eye cancer of unspecified histology, occurred in obligate gene carriers...
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studiesA Antoniou
Cancer Research U K Genetic Epidemiology Unit, Department of Public Health, University of Cambridge, Cambridge, United Kingdom
Am J Hum Genet 72:1117-30. 2003..The variation in risk by age at diagnosis of index case is consistent with the effects of other genes modifying cancer risk in carriers...
Risk models for familial ovarian and breast cancerA C Antoniou
CRC Genetic Epidemiology Unit, Institute of Public Health, University of Cambridge, Cambridge, United Kingdom
Genet Epidemiol 18:173-90. 2000..The high penetrance estimate for ovarian cancer, compared with other studies, suggests that modifying genetic or environmental factors may be important determinants of risk...
A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genesA C Antoniou
CRC Genetic Epidemiology Unit, Institute of Public Health, Strangeways Research Laboratory, Worts Causeway, University of Cambridge, Cambridge CB1 8RN, UK
Br J Cancer 86:76-83. 2002..The modifying effect may explain the previously reported differences between population based estimates for BRCA1/2 penetrance and estimates based on high-risk families...
Family history and the risk of breast cancer: a systematic review and meta-analysisP D Pharoah
Institute of Public Health, Cambridge, UK
Int J Cancer 71:800-9. 1997..8 (CI = 1.6, 2.0); mother and sister, RR = 3.6 (CI = 2.5, 5.0); and a second-degree relative, RR = 1.5 (CI = 1.4, 1.6). Risks were increased in subjects under age 50 and when the relative had been diagnosed before age 50...
The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genesS A Gayther
Department of Oncology, Cancer Research Campaign, Strangeways Research Laboratory, Cambridge, United Kingdom
Am J Hum Genet 65:1021-9. 1999..We discuss the implications for genetic testing and clinical management of familial ovarian cancer arising from the data presented in these studies...
Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS)M O Leach
MARIBS Study Office, Section of Magnetic Resonance, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK
Lancet 365:1769-78. 2005..Our aim was, therefore, to compare contrast enhanced magnetic resonance imaging (CE MRI) with mammography for screening...
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studiesA C Antoniou
J Med Genet 42:602-3. 2005..These estimates appear to be consistent with the observed prevalence of the mutations in the Ashkenazi Jewish population...
The BOADICEA model of genetic susceptibility to breast and ovarian cancerA C Antoniou
Cancer Research UK, Genetic Epidemiology Unit, Strangeways Research Laboratory, Department of Public Health and Primary Care, Worts Causeway, Cambridge CB1 8RN, UK
Br J Cancer 91:1580-90. 2004..We conclude that this model provides a rational basis for risk assessment in individuals with a FH of breast or ovarian cancer...
Single-nucleotide polymorphisms in the RB1 gene and association with breast cancer in the British populationF Lesueur
Department of Oncology, University of Cambridge, Strangeways Research Laboratories, UK
Br J Cancer 94:1921-6. 2006..Replication studies are needed to confirm the associations with breast cancer...
Interactions between genes involved in the antioxidant defence system and breast cancer riskM Z Oestergaard
Department of Public Health and Primary Care, Strangeways Research Laboratories, Cambridge CB1 8RN, UK
Br J Cancer 95:525-31. 2006..12) nor a fifth round with more balanced proportion of missing values between cases and controls (P=0.17) was significant...
Polygenic inherited predisposition to breast cancerB A J Ponder
Department of Oncology and Public Health and Cancer Research UK Genetic Epidemiology Unit, Strangeways Research Laboratories, University of Cambridge, UK
Cold Spring Harb Symp Quant Biol 70:35-41. 2005..A key unanswered question is the "genetic architecture" of predisposition-that is, strong or weak alleles, common or rare. We describe a genome-wide scan designed to provide a first-pass answer to this question...
Models of genetic susceptibility to breast cancerA C Antoniou
Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK
Oncogene 25:5898-905. 2006..Such a model of susceptibility has implications for both risk prediction and for future gene identification studies...
HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancerP R Benusiglio
Strangeways Research Laboratory, Cancer Research UK Department of Oncology, University of Cambridge, UK, and Department of Internal Medecine, Hopital Cantonal Universitaire de Geneve, Switzerland
Br J Cancer 95:1689-95. 2006..We are therefore likely to have tagged any common variants present in our population. In summary, we found no association between common genetic variation in the 17q21 ERBB2 amplicon and breast cancer risk in British women...
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensionsA C Antoniou
Cancer Research UK, Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
Br J Cancer 98:1457-66. 2008..BOADICEA can be used to predict carrier probabilities and cancer risks to individuals with any family history, and has been implemented in a user-friendly Web-based program (http://www.srl.cam.ac.uk/genepi/boadicea/boadicea_home.html)...
Common variants in mismatch repair genes and risk of colorectal cancerT Koessler
Cancer Research UK Department of Oncology, Strangeways Research Laboratory, University of Cambridge, Worts Causeway, Cambridge, UK
Gut 57:1097-101. 2008..To assess the putative associations between common variants in MMR genes and CRC, we performed a genetic case-control study using a single-nucleotide polymorphism (SNP) tagging approach...
A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndromeR Wooster
Section of Molecular Carcinogenesis, Institute of Cancer Research, Belmont, Sutton, Surrey, UK
Nat Genet 2:132-4. 1992..This is the first report of a germline mutation in a member of the steroid/thyroid hormone receptor superfamily associated with the development of cancer...
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinicsA C Antoniou
Cancer Research UK, Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK
J Med Genet 45:425-31. 2008..Several algorithms that predict the likelihood of carrying a BRCA1 or a BRCA2 mutation are currently used in clinical practice to identify such individuals...
Apparent human BRCA1 knockout caused by mispriming during polymerase chain reaction: implications for genetic testingB Kuschel
CRC Human Cancer Genetics Research Group, Department of Oncology, Strangeways Research Laboratories, Cambridge, England
Genes Chromosomes Cancer 31:96-8. 2001..This may have major implications for the sensitivity of all polymerase chain reaction-based mutation-detection methods in clinical genetic testing laboratories...
CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriersL Kadouri
Sharett Institute of Oncology, Hebrew University Hadassah Medical Center, Jerusalem, Israel
Br J Cancer 85:36-40. 2001..We conclude that, in contrast to previous observations, if there is any effect of the AR repeat length on BRCA1 penetrance, it is likely to be weak...
CYP17 promoter polymorphism and breast cancer in Australian women under age forty yearsA B Spurdle
Cancer Unit, Joint Experimental Oncology Programme, The Queensland Institute of Medical Research, and The University of Queensland, Brisbane, Australia
J Natl Cancer Inst 92:1674-81. 2000..Because steroid hormone exposure is known to influence breast cancer risk, we conducted a population-based, case-control-family study to assess the relationship between the CYP17 promoter polymorphism and early-onset breast cancer...
Polymorphisms in CYP1A1 and smoking: no association with breast cancer riskV M Basham
CRC Human Cancer Genetics Group, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK
Carcinogenesis 22:1797-800. 2001..9 (0.7-1.1), Val/Val OR = 2.3 (0.4-12), and Val carrier OR = 1.0 (0.9-1.1)]...
HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of diseaseJ C Meitz
Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
Br J Cancer 87:905-8. 2002..50, 95% CI 0.79-2.85) or to patients diagnosed >55 years (OR=1.27, 95% CI 0.59-2.74). We conclude that any association between the Thr541 variant and prostate cancer is likely to be weak...
Association between the GCG polymorphism of the selenium dependent GPX1 gene and the risk of young onset prostate cancerZ Kote-Jarai
Section of Cancer Genetics, The Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, Surrey, UK
Prostate Cancer Prostatic Dis 5:189-92. 2002..67; 95% CI: 0.97-2.87). The result of this study suggests that the GPX1 genotype is unlikely to be associated with the risk of developing prostate cancer...
The UK national study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS)M O Leach
Section of Magnetic Resonance, The Institute of Cancer Research and The Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT, UK
J Exp Clin Cancer Res 21:107-14. 2002..15 cancers have been detected to date, from a total of 1236 screening measurements. This event rate and the tumour grades reported are compared with recent reports from other studies in women at high risk of breast cancer...
ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancerT Stankovic
CRC Institute for Cancer Studies, The Medical School, University of Birmingham, United Kingdom
Am J Hum Genet 62:334-45. 1998..We also show that 25% of all A-T patients carried in-frame deletions or missense mutations, many of which were also associated with expression of mutant ATM protein...
Familial cylindromatosis (turban tumour syndrome) gene localised to chromosome 16q12-q13: evidence for its role as a tumour suppressor geneP J Biggs
Section of Molecular Carcinogenesis, Institute of Cancer Research, Haddow Laboratories, Belmont, Sutton, Surrey, UK
Nat Genet 11:441-3. 1995..Using markers close to the cylindromatosis gene, consistent loss of the wild-type allele was observed in 19 tumours from four individuals in the two families, indicating that the gene is likely to be a tumour suppressor gene...
A common variant in BRCA2 is associated with both breast cancer risk and prenatal viabilityC S Healey
CRC Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK
Nat Genet 26:362-4. 2000..82 in females and 1.38 in males. Therefore, this variant of BRCA2 appears also to affect fetal survival in a sex-dependent manner...
Testicular microlithiasis as a familial risk factor for testicular germ cell tumourJ Coffey
Testicular Cancer Genetics Team, Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
Br J Cancer 97:1701-6. 2007..We suggest that TM is an alternative manifestation of a TGCT susceptibility allele...
Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breastL G Fulford
The Breakthrough Breast Cancer Research Centre, London, UK
Histopathology 49:22-34. 2006..Currently, they are not identified in routine practice and no morphological guidelines exist to aid their identification. The aim of this study was to analyse the histological features of CK14+ IDC...
ATM polymorphisms as risk factors for prostate cancer developmentS Angele
DNA Repair Group, International Agency for Research on Cancer, 150 cours Albert Thomas, 69373 Lyon, France
Br J Cancer 91:783-7. 2004..These results provide evidence that the presence of common variants in the ATM gene, may confer an altered cellular phenotype, and that the ATM 3161C>G variant might be associated with prostate cancer risk...
Role of MC1R variants in uveal melanomaN Hearle
Haddow Laboratories, Section of Cancer Genetics, Institute of Cancer Research, 15 Cotswold Road, Sutton SM2 5NG, UK
Br J Cancer 89:1961-5. 2003..We interpret the data as indicating that MC1R variants do not appear to be major determinants of susceptibility to uveal melanoma...
Common polymorphisms in checkpoint kinase 2 are not associated with breast cancer riskB Kuschel
Cancer Research UK Human Cancer Genetics Research Group, Department of Oncology, Strangeways Research Laboratories, Cambridge CB1 8RN, United Kingdom
Cancer Epidemiol Biomarkers Prev 12:809-12. 2003..It is also unlikely that other, as yet unidentified, common polymorphisms that affect risk are present in the gene in the British population...
Germline mutations in fumarate hydratase (FH) do not predispose to prostate cancerS Bevan
Molecular and Population Genetics Team, Section of Cancer Genetics, Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, Surrey, UK
Prostate Cancer Prostatic Dis 6:12-4. 2003..No pathogenic mutations in FH were identified in any of the cases. This data makes it highly unlikely that mutations in FH confer susceptibility to prostate cancer...
